H.C. Wainwright analyst Yi Chen reiterated a Hold rating on CareDx (CDNA – Research Report) today. The company’s shares closed yesterday at $8.50.
Chen covers the Healthcare sector, focusing on stocks such as Anixa Biosciences, Oculis Holding, and EyePoint Pharmaceuticals. According to TipRanks, Chen has an average return of -32.6% and a 21.88% success rate on recommended stocks.
CareDx has an analyst consensus of Hold, with a price target consensus of $12.00.
See today’s best-performing stocks on TipRanks >>
CDNA market cap is currently $460.4M and has a P/E ratio of -5.43.
Based on the recent corporate insider activity of 75 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CDNA in relation to earlier this year. Last month, George Bickerstaff, a Director at CDNA bought 19,453.00 shares for a total of $99,064.82.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CareDx, Inc. operates as a transplant diagnostics company,which discovers, develops, and commercializes diagnostic solutions. Its product includes AlloMap, AlloSure, and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.
Read More on CDNA:
